5,425 Shares in Humana Inc. $HUM Purchased by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 5,425 shares of Humana Inc. ($HUM), worth approximately $1.4 million, during the first quarter.
• Humana reported Q2 earnings of $6.27 per share, missing estimates by $0.05, although its revenue of $32.39 billion exceeded expectations.
• The company announced a quarterly dividend of $0.885 per share, which equates to an annualized yield of 1.3%.

AG2R LA Mondiale Gestion D Actifs purchased a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,425 shares of the insurance provider's stock, valued at approximately $1,435,000.

A number of other large investors have also recently made changes to their positions in the company. Voya Investment Management LLC boosted its stake in shares of Humana by 7.7% during the 1st quarter. Voya Investment Management LLC now owns 45,190 shares of the insurance provider's stock worth $11,957,000 after purchasing an additional 3,221 shares during the period. First Hawaiian Bank boosted its stake in shares of Humana by 9.2% during the 1st quarter. First Hawaiian Bank now owns 13,811 shares of the insurance provider's stock worth $3,654,000 after purchasing an additional 1,164 shares during the period. Strs Ohio purchased a new position in shares of Humana during the 1st quarter worth about $9,790,000. Acadian Asset Management LLC purchased a new position in shares of Humana during the 1st quarter worth about $3,726,000. Finally, Focus Partners Wealth boosted its stake in shares of Humana by 104.2% during the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider's stock worth $1,701,000 after purchasing an additional 3,281 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 0.8%

NYSE:HUM opened at $276.36 on Friday. Humana Inc. has a one year low of $206.87 and a one year high of $325.75. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market cap of $33.24 billion, a P/E ratio of 21.21, a P/E/G ratio of 1.64 and a beta of 0.44. The firm has a 50-day simple moving average of $265.34 and a 200-day simple moving average of $257.20.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the prior year, the firm posted $6.96 EPS. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. Equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana's payout ratio is 27.17%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays boosted their price objective on shares of Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a research report on Friday, September 5th. Truist Financial lowered their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Royal Bank Of Canada boosted their price objective on shares of Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Piper Sandler lowered their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $289.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.